Search
    • 1 min read

10/08/19 A Better Future

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals...more

1 view
    • 1 min read

7/25/19 Acupath First Commercial Lab to Offer URO17™, Innovative New Biomarker

PLAINVIEW, N.Y. and CAMPBELL, Calif., July 25, 2019 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has licensed Acupath to incorporate its URO17™ ...more

0 views

Copyright © All Rights Reserved

LEGAL NOTICE; By accessing, browsing and/or otherwise using this website, you acknowledge that you have read, understood, and are bound by the KDx Diagnostics Inc. Website Terms and Conditions, and Privacy Policy and shall comply with all applicable laws and regulations. If you do not agree to these terms, do not use this website. Additionally, this website contains information on products that is targeted to many different audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that KDx Diagnostics Inc. does not take any responsibility for your decision to access any such information on this website that may not comply with a legal process, regulation, registration or usage in the country of your origin.

​​

​